Third Time Is The Charm For Thalomid Myeloma Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Celgene’s sNDA for the oncology indication after issuing two “approvable” letters.
You may also be interested in...
Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.
Millennium Chief Medical Officer Nancy Simonian: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm's first year of profitability, the multiple myeloma market and current Velcade strategy following its copromotion deal with J&J.
Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.